Raymond James Financial Inc. bought a new position in Novanta Inc. (NASDAQ:NOVT – Free Report) during the 4th quarter, Holdings Channel.com reports. The institutional investor bought 51,717 shares of the technology company’s stock, valued at approximately $7,901,000.
Several other hedge funds have also modified their holdings of the stock. Arizona State Retirement System lifted its position in Novanta by 0.7% during the fourth quarter. Arizona State Retirement System now owns 10,412 shares of the technology company’s stock valued at $1,591,000 after buying an additional 76 shares in the last quarter. Nicolet Advisory Services LLC lifted its position in shares of Novanta by 5.9% during the third quarter. Nicolet Advisory Services LLC now owns 2,502 shares of the technology company’s stock worth $430,000 after purchasing an additional 139 shares in the last quarter. M&T Bank Corp lifted its position in shares of Novanta by 4.5% during the third quarter. M&T Bank Corp now owns 3,619 shares of the technology company’s stock worth $647,000 after purchasing an additional 155 shares in the last quarter. Empowered Funds LLC acquired a new position in shares of Novanta during the fourth quarter worth $26,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Novanta by 3.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,147 shares of the technology company’s stock worth $1,458,000 after purchasing an additional 249 shares in the last quarter. 98.35% of the stock is owned by institutional investors and hedge funds.
Novanta Trading Down 0.5 %
NASDAQ NOVT opened at $133.52 on Friday. The company’s fifty day simple moving average is $144.31 and its 200-day simple moving average is $159.85. Novanta Inc. has a 52 week low of $131.03 and a 52 week high of $187.12. The company has a current ratio of 2.79, a quick ratio of 1.81 and a debt-to-equity ratio of 0.61. The stock has a market cap of $4.80 billion, a P/E ratio of 79.95 and a beta of 1.34.
Wall Street Analyst Weigh In
Separately, Robert W. Baird reduced their target price on shares of Novanta from $169.00 to $160.00 and set a “neutral” rating on the stock in a research report on Monday, March 3rd.
Get Our Latest Stock Report on NOVT
About Novanta
Novanta, Inc engages in the provision of core technology solutions to healthcare and advanced industrial original equipment manufacturers. It operates through the following segments: Photonics, Vision, and Precision Motion. The Photonics segment designs, manufactures, and markets photonics-based solutions, including laser scanning and laser beam delivery, CO2 laser, continuous wave and ultrafast laser, and optical light engine products.
Recommended Stories
- Five stocks we like better than Novanta
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Why Williams-Sonoma Will Hit Fresh Highs in 2025
- Trading Stocks: RSI and Why it’s Useful
- Alphabet Stock Becomes a Low-Risk, High-Reward Play
- What is the MACD Indicator and How to Use it in Your Trading
- Affirm Stock: Should You Buy the Dip After Walmart Setback?
Want to see what other hedge funds are holding NOVT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novanta Inc. (NASDAQ:NOVT – Free Report).
Receive News & Ratings for Novanta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novanta and related companies with MarketBeat.com's FREE daily email newsletter.